Cancer Institute’s SHOCKING Ivermectin Gamble

April 10, 2026

The National Cancer Institute has launched a taxpayer-funded investigation into ivermectin’s cancer-killing potential, despite zero evidence the cheap deworming drug works in humans—a move that has some researchers “shocked and appalled” while others see hope for patients failed by the high-priced pharmaceutical establishment.

Story Snapshot

NCI Director Anthony Letai announced in January 2026 that the institute is conducting preclinical studies on ivermectin’s ability to kill cancer cells, responding to public pressure and laboratory reports
Lab studies show ivermectin inhibits cancer cell growth in colorectal, breast, and lung cancers through mechanisms like apoptosis and cell cycle arrest, but a small human trial showed no benefit
The drug costs roughly $0.10 per dose compared to expensive chemotherapy, raising questions about whether Big Pharma has ignored viable treatments that don’t generate massive profits
Some cancer researchers criticized the NCI’s focus on ivermectin as a distraction from proven therapies, highlighting deep divisions over drug repurposing and federal research priorities

Federal Agency Investigates Antiparasitic Drug for Cancer

NCI Director Anthony Letai disclosed at a January 2026 event hosted by allies of Robert F. Kennedy Jr. that his agency is conducting preclinical research on ivermectin’s potential to kill cancer cells. The announcement followed years of laboratory studies suggesting the antiparasitic drug, discovered in the 1970s from soil bacteria, may inhibit tumor growth through multiple pathways including Wnt signaling suppression and mitochondrial dysfunction. Letai stated there were “enough reports” to warrant federal investigation, funded partly by NIH resources allocated to drug repurposing efforts.

Laboratory Evidence Versus Human Clinical Reality

Peer-reviewed research published in Frontiers in Pharmacology and other journals demonstrates ivermectin inhibits colorectal cancer cell lines at concentrations of 2.5 to 30 micromolar by generating reactive oxygen species, triggering apoptosis, and arresting cells in S-phase. Preclinical models across colorectal, pancreatic, lung, and melanoma cancers show dose-dependent antiproliferative effects, with some studies reporting synergy when combined with chemotherapy drugs like gemcitabine through mTOR and STAT3 pathway suppression. Despite these laboratory findings spanning two decades, no phase III clinical trials have validated efficacy in humans. An ongoing NCI trial testing ivermectin plus pembrolizumab in metastatic triple-negative breast cancer yielded preliminary data showing no patient benefit, underscoring the gap between petri dish promise and bedside reality.

Political Dynamics and Public Pressure Shape Research Priorities

The timing of NCI’s ivermectin investigation reflects political currents running through the Trump administration’s second term, with Anthony Letai appointed as NCI Director in September 2025. The drug gained notoriety during COVID-19 controversies, fueling online speculation about suppressed cancer cures that pharmaceutical companies allegedly ignore due to ivermectin’s expired patents and negligible profit margins compared to proprietary oncology drugs costing tens of thousands annually. RFK Jr.’s network and grassroots advocates pushed federal health agencies to examine repurposed medications, arguing that government researchers answer to Big Pharma rather than desperate patients seeking affordable alternatives. This populist pressure collided with institutional skepticism, as one cancer researcher told STAT News they were “shocked and appalled” by the NCI’s decision to dedicate resources to ivermectin when no human evidence supports its use.

Economic Stakes and Access Questions Loom Large

Ivermectin’s rock-bottom cost creates a paradigm challenge for an oncology market built on high-margin treatments requiring insurance coverage most Americans struggle to afford. If validated through rigorous human trials, a drug available for roughly ten cents per dose could democratize cancer care globally, particularly benefiting low-resource regions where chemotherapy remains financially out of reach for millions. However, the monotherapy failures in early trials suggest any future role would likely involve combination regimens, complicating the economic calculus. The controversy exposes deeper frustrations shared across the political spectrum: Americans increasingly believe their government serves corporate interests over public health, whether through regulatory capture favoring pharmaceutical giants or research bureaucracies dismissing inexpensive options without thorough investigation. The NCI’s preclinical pivot attempts to address this credibility gap, yet risks amplifying false hope if laboratory mechanisms fail to translate into clinical cures—a pattern repeatedly seen in cancer drug development.